Mark W. Hahn

2022 - Verona Pharma plc

In 2022, Mark W. Hahn earned a total compensation of $4.8M as Chief Financial Officer at Verona Pharma plc, a 546% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$331,531
Salary$430,450
Stock Awards$3,983,498
Other$22,401
Total$4,767,880

Hahn received $4M in stock awards, accounting for 84% of the total pay in 2022.

Hahn also received $331.5K in non-equity incentive plan, $430.5K in salary and $22.4K in other compensation.

Rankings

In 2022, Mark W. Hahn's compensation ranked 678th out of 5,683 executives tracked by ExecPay. In other words, Hahn earned more than 88.1% of executives.

ClassificationRankingPercentile
All
678
out of 5,683
88th
Division
Manufacturing
295
out of 3,091
91st
Major group
Chemicals And Allied Products
90
out of 1,406
94th
Industry group
Drugs
77
out of 1,307
94th
Industry
Pharmaceutical Preparations
56
out of 949
94th
Source: SEC filing on March 21, 2023.

Hahn's colleagues

We found two more compensation records of executives who worked with Mark W. Hahn at Verona Pharma plc in 2022.

2022

David Zaccardelli

Verona Pharma plc

Chief Executive Officer

2022

Kathleen Rickard

Verona Pharma plc

Chief Medical Officer

News

You may also like